Novacyt S.A.
Novacyt S.A. is an international molecular diagnostics company headquartered in the UK (parent registered in France) providing integrated technologies and services centred on genomic medicine. It operates through two reporting segments: Yourgene Health (clinical in vitro diagnostics across reproductive health, precision medicine and infectious disease, plus Ranger DNA-sample-prep instrumentation) and Primer Design (qPCR research reagents/assays for life sciences, food/water/agriculture and animal health). FY2025 revenue was £20.0m with a £7.8m EBITDA loss and £19.1m year-end cash.
FY2025 in sixty seconds
year to 31 Dec 2025 · approved 29 Apr 2026 · 100 pages · Company website
Novacyt S.A. is a UK-based company that makes tests and equipment for genetic and diagnostic laboratories. In the year to 31 December 2025 its revenue rose slightly to £20.0m, from £19.6m. It still made a loss, of £22.9m after tax, though that was smaller than the £41.8m loss the year before.
Higher sales came mainly from prenatal blood tests and a new laboratory instrument, partly offset by lower sales of research products. The loss included a £14,446k write-down in the value of its Yourgene Health business, plus restructuring costs from closing sites. The previous year's figures were flattered by a one-off £19.8m gain from releasing money set aside for a dispute with the UK health department.
Cash fell to £19.1m from £30.5m. Apart from property leases, the company has no borrowings. It raised no money from shareholders during the year, though a small share issue followed in March 2026 to help pay for buying an Australian distributor. No dividend was paid. Management expects double-digit revenue growth and continued progress towards profit before one-off costs. The auditors gave a clean opinion, and the directors forecast enough cash to last into April 2027.
NIPT (non-invasive prenatal testing) workflows under the IONA/Yourgene Nx brands
NIPT technologies delivered double-digit growth in 2025 following new contract wins including NHS St George's and a 4-year Iceland national tender
page 11Gross margin held at ~63% underlying (2024 underlying also 63% once DHSC one-off removed)
Gross profit £12.6m (63%) vs 2024 £32.1m (163%, inflated by £19.8m one-off provision release); underlying 2024 gross profit £12.3m (63%)
page 15Looking ahead, the Group is well positioned to drive double-digit revenue growth and continue progressing towards EBITDA profitability
page 6No dividends paid since inception and none proposed for FY2025; future dividend policy will form part of a wider capital allocation review so the Group can continue investing in R&D, manufacturing and commercial activities
page 249 years on one page · FY2015–FY2025
| Line | FY2015locked | FY2016locked | FY2017locked | FY2018locked | FY2019locked | FY2020locked | FY202312/23 | FY202412/24 | FY202512/25 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||
| Operating profit | |||||||||
| Profit for the year | |||||||||
| Basic EPS | |||||||||
| Free cash flow | |||||||||
| Net debt (negative = net cash) | |||||||||
| Shares in issue | |||||||||
| Operating margin | |||||||||
| Return on capital employed | — |
GBP millions, negatives in brackets. Per-share lines in pence. Share counts in millions. Margins and returns as percentages, calculated from the filed figures. later is what a following report restated the figure to; vs is a second reading that disagrees. The figure shown is the one the original filing printed, and both readings are kept. Click any figure: opens the report page it was read from, highlighted; shows how it was calculated.
5 figures restated in a later report
Every figure is read again from the following year’s report: 126 confirmed, 6 differ, 5 restated.
No figure has been restated: every figure a later report printed again, it printed the same.
5 more figures were restated in FY2015 to FY2020, which a free account opens.